TRADD-mediated pyroptosis contributes to diabetic cardiomyopathy

Yang-Yang Zheng1,2, Dan-Ning Shen1, Xiao-Lu Peng1

  • 1Department of Pharmacology, School of Pharmacy, Nantong University, Nantong, 226001, China.

PubMed

Insights

Tumor necrosis factor receptor-associated death domain protein (TRADD) drives pyroptosis in diabetic cardiomyopathy. Inhibiting TRADD improved heart function and reduced cell death in diabetic mice and heart cells, offering a new treatment strategy.

Area of Science:

  • Cardiology
  • Cell Death Mechanisms
  • Molecular Biology

Background:

  • Diabetic cardiomyopathy (DCM) is a leading cause of heart failure, often driven by regulated cell death pathways like pyroptosis.
  • Tumor necrosis factor receptor-associated death domain protein (TRADD) is implicated in cardiovascular disorders but its role in pyroptosis during DCM is unclear.

Purpose of the Study:

  • To investigate the role and underlying mechanisms of TRADD in pyroptosis within the context of diabetic cardiomyopathy.
  • To explore TRADD as a potential therapeutic target for DCM.

Main Methods:

  • Established streptozotocin (STZ)-induced diabetic mouse and high glucose (HG)-treated cardiomyocyte models.
  • Assessed cardiac function, hypertrophy, fibrosis, and pyroptosis markers following TRADD knockdown or inhibition.
  • Investigated the transcriptional regulation of TRADD by X-box binding protein 1 (XBP1) under HG conditions.

Main Results:

  • TRADD expression was significantly upregulated in diabetic mouse hearts and HG-treated cardiomyocytes.
  • TRADD knockdown improved cardiac function and attenuated cardiac remodeling and pyroptosis in diabetic mice.
  • TRADD inhibition or knockdown reduced cell injury and pyroptosis in HG-treated cardiomyocytes.
  • High glucose treatment increased XBP1 expression, which bound to the TRADD promoter, enhancing TRADD expression.

Conclusions:

  • TRADD-mediated pyroptosis is a key contributor to the pathogenesis of diabetic cardiomyopathy.
  • Targeting TRADD presents a promising novel therapeutic strategy for managing DCM.